In the wake of the RACE Act, identifying and partnering with key stakeholders, namely patient organizations and academia, will enable companies to efficiently overcome key barriers.
This whitepaper offers a high-level orientation around the key barriers to readiness and critical success factors for companies navigating the pediatric oncology space. The primary focus of this whitepaper is on how collaboration with patient organizations will be critical to overcoming the obstacles most companies will encounter.
Together, the elements of this whitepaper aim to support collaboration between industry and patient organizations as a valuable strategy to ensuing readiness for the RACE Act.
The Benefits of Home Health Care in Pediatric Clinical Trials
Home health care has long been utilized in clinical trials. With the increased interest in adopting clinical trial models like decentralized clinical…
Search for a Cure: Type 1 Diabetes
In our first issue of Industry Watch for 2021, we’re bringing our readers insights from a founding member of the Human Genome Project, looking at…